Sexually Transmitted Diseases

Ben Berkhout, PhD, discusses if CRISPR/Cas9 will be a new antiviral strategy for the eradication of HIV.

Missing visits is a warning sign that patients may discontinue PrEP, according to a recent study that found only 38% of participants remained in treatment over 12 months.

Sexual risk behavior was significantly lower among men in community supervision programs who participated in couples-based intervention, in a recent study.

In a new trial, an experimental antibody suppressed HIV in patients on short-term pause from their daily antiretroviral therapy regimens.

A study using monkeys provides an intriguing glimpse of the possibilities of using CRISPR gene editing technology to knock out HIV reserves in humans.

Melanie Nicol, PharmD, PhD, explores how DMPA hormonal contraception affects women's HIV risk.

Jose Arribas, MD, discusses the challenges in the field of long-acting injectable therapy for the treatment, management, and even prevention of HIV.

Subcutaneous implants are 1 promising strategy to address suboptimal adherence to pre-exposure prophylaxis (PrEP) for HIV, and a recent in silico simulation examined pharmacokinetic profiles and safety of tenofovir alafenamide implants.

Brian Woodfall, MD, discusses how long-acting injectables offer a new treatment option for patients with HIV in terms of long-term therapy.

Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reacts to news of the London patient, the second person cured of HIV infection.

With the proper use of antiretroviral therapy and pre-exposure prophylaxis, the risk of HIV transmission has never been lower. So why do some practitioners hesitate to endorse condomless sex?

Among gay and bisexual men, receipt of PrEP at study enrollment was linked with an increased incidence of STIs, but 25% of participants accounted for 76% of all STIs.

Dolutegravir/lamivudine (Dovato) becomes the first 2-drug, fixed-dose complete treatment for treatment-naive patients with HIV.

Saye Khoo, MD, advocates for a more appropriate, stratified, risk-based approach to prescribing dolutegravir in pregnant women.

Bluma Brenner, PhD, explains the driving factors behind the push for new antiretroviral drugs for HIV treatment.

Contagion® is reflecting on the advancements in treatment and prevention that have been made in infectious diseases while identifying areas that need further improvement to reduce preventable deaths globally.

Although preventing the transmission of HIV from mother to baby is of paramount importance, we cannot overlook other health issues that may crop up later in life for children born to women with HIV.

Brian Woodfall, MD, shares his opinion on some of the biggest advancements in HIV treatment and prevention.

What’s the 411 on 2-1-1?

A 1-month course of rifapentine plus isoniazid is non-inferior to 9 months of isoniazid alone for preventing TB in individuals with HIV, a study reports.

The new single-tablet regimen provides a safe and effective treatment option for patients with HIV.

A neural model suggests the frontal lobe is affected early on in HIV disease and the caudate/striatum area is affected when neurocognitive disorder symptoms develop.

Paul Sax, MD, reacts to the ATLAS and FLAIR studies on long-acting injectable therapy.

A new study found an average decrease of sexual anxiety by 0.27 points when participants were on PrEP compared with before treatment.

Susan Swindells, MBBS, provides an overview of long-acting injectable cabotegravir + rilpivirine for clinicians.